Le Lézard
Classified in: Business
Subjects: PDT, ACC

Frazier & Deeter Announces Tax Dispute Resolution Services


Top 50 accounting and advisory firm expands service offering to help clients navigate tax controversies.

ATLANTA, July 20, 2023 /PRNewswire-PRWeb/ -- Frazier & Deeter (FD), a Top 50 accounting & advisory firm, is pleased to announce its Tax Dispute Resolution service line, which allows the firm to offer strategic counsel and expert guidance to clients navigating tax controversies.

FD's Tax Dispute Resolution is led by James Robertson, Tax Compliance & Controversy Specialist. Robertson works with high-net-worth individuals and families in the preparation of tax returns, tax planning and facilitating tax compliance. With over a decade of experience, his expertise includes complex tax issues, tax reduction strategies and tax issue resolution. In addition to his local appearances on WSB-TV, WXIA 11 Alive, Peachtree TV and nationally on the Fox News Channel, he has been featured in articles in the AJC, Atlanta Business Chronicle and the Marietta Daily Journal.

"We are excited to officially expand our service offering to include tax dispute resolution," stated Partner Jeremy Sperring, FD's Head of Tax. "James' extensive expertise in this area, in addition to his contributions to national print and televised media, make him an invaluable resource to FD's tax team and our clients."

To learn more about FD's Tax Dispute Resolution and the firm's comprehensive range of services, visit https://www.frazierdeeter.com/services/tax/tax-dispute-resolution/.

About Frazier & Deeter
Frazier & Deeter is an award-winning Top 50 accounting & advisory firm headquartered in Atlanta, Georgia. The firm provides a wide range of tax, audit and advisory services to meet the emerging needs of clients as they evolve. FD and its family of brands serve clients, from the Fortune Global 500 companies to growing small businesses, through six offices across the US, two in the UK and one in India. The firm has been recognized repeatedly as a Best of the Best Accounting firm, a Best Firm to Work For® and a Best Firm for Women in Leadership. FD's brand promise is Investing in Relationships to Make a Difference®.

Media Contact

Katelyn Brown, Frazier & Deeter, 770.880.0372, katelyn.brown@frazierdeeter.com

 

SOURCE Frazier & Deeter


These press releases may also interest you

at 12:10
Stronger Than Ever: Adani Portfolio Delivers Record Performance
In line with their commitment to upholding the highest standards of transparency, below is the Adani Portfolio's Credit and Result compendium for financial year 2023-24. The performance in FY24 and the past five years signify the strength and...

at 11:00
Linker Vision to Accelerate Vision AI Adoption Across Enterprise Applications with Large Vision Models, in Collaboration with NVIDIA
Linker Vision, a pioneer in AI technology, is proud to announce a collaboration with NVIDIA aimed at accelerating vision AI adoption across enterprise applications with large vision models (LVMs). Through this collaboration, Linker Vision is poised...

at 10:45
ConcertAI to Advance Translational and Clinical Development Solutions in Collaboration with NVIDIA
ConcertAI, the leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration with NVIDIA to advance a broad set of translational and clinical development solutions within the ConcertAI CARA AI platform....

at 08:30
Vention to democratize industrial automation using NVIDIA AI technologies
Vention, the company behind the cloud-based Manufacturing Automation Platform (MAP), today announced a collaboration with NVIDIA to bring industrial automation technology to small and medium manufacturers by using NVIDIA AI and accelerated computing...

1 jun 2024
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung...

1 jun 2024
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

More news about Business...


News published on and distributed by: